BioTuesdays

Tag - Thomas Smith

Disc-Medicine-Logo

SVB starts Disc Medicine at OP; PT $36

SVB Securities launched coverage of Disc Medicine (NASDAQ:IRON) with an “outperform” rating and $36 price target. The stock closed at $24.39 on Feb. 27. Disc Medicine is a clinical-stage biopharmaceutical company...

Trevi Logo

SVB starts Trevi Therapeutics at OP; PT $6

SVB Securities initiated coverage of Trevi Therapeutics (NASDAQ:TRVI) with an “outperform” rating and $6 price target. The stock closed at $1.99 on Nov. 21. TRVI is a clinical-stage biopharmaceutical company developing...

MoonLake Logo

SVB starts Moonlake at OP; PT $17

SVB Securities launched coverage of Moonlake Immunotherapeutics (NASDA:MLTX) with an “outperform” rating and $17 price target. The stock closed at $9.01 on Aug. 24. Moonlake is a clinical-stage biopharmaceutical company...

Dice-Therapeutics

SVB Leerink starts DICE Therapeutics at OP; PT $46

SVB Leerink launched coverage of Dice Therapeutics (NASDAQ:DICE) with an “outperform” rating and $46 price target. The stock closed at $26.49 on Oct. 8. DICE is a biopharmaceutical company leveraging its proprietary...

RAPT-Therapeutics

SVB Leerink starts RAPT Therapeutics at OP; PT $49

SVB Leerink launched coverage of RAPT Therapeutics (NASDAQ:RAPT) with an “outperform” rating and a $49 price target. The stock closed at $33.07 on Aug. 11. RAPT is a clinical-stage biopharmaceutical company developing...

Vectiv-Bio

SVB Leerink starts VectivBio at OP; PT $28

SVB Leerink launched coverage of VectivBio Holding AG (NASDAQ:VECT) with an “outperform” rating and $28 price target. The stock closed at $15.21 on May 3. VectivBio is focused on developing treatments for severe rare...

Connect-Biopharma-Logo

SVB Leerink starts Connect Biopharma at OP; PT $32

SVB Leerink launched coverage of Connect Biopharma Holdings (NASDAQ:CNTB) with an “outperform” rating and price target of $32. The stock closed at $17.05 on April 12. Connect is a clinical-stage biotech headquartered in...

Prometheus-Biosciences-Logo

Analysts start Prometheus Biosciences at OP and buy

Analysts for Stifel and SVB Leerink initiated coverage of Prometheus Biosciences (NASDAQ:RXDX) with “outperform” and “buy” ratings, respectively, and price targets of $25 and $34, respectively. The stock closed at $19...

Eledon-Pharmaceuticals

SVB Leerink starts Eledon Pharma at OP; PT $34

SVB Leerink launched coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with an “outperform” rating and a $34 price target. The stock closed at $14.99 on Feb. 5. Eledon is developing AT-1501, a potentially best-in-class...